Kara Hoisington
Endocrinology, Diabetes & Metabolism · Lansing, MINPI 1588877419
Payments from drug & device makers
Across 612 payments — averaging $291.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$74K
- Sanofi-aventis U.S. LLC$36K
- AstraZeneca$29K
- Lilly USA, LLC$17K
- Amgen$15K
- Boehringer Ingelheim$6K
- plus $2K from 31 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 267 | $73,561 |
| Sanofi-aventis U.S. LLC | 63 | $35,500 |
| AstraZeneca(2 entities) | 68 | $29,180 |
| Lilly USA, LLC | 40 | $17,176 |
| Amgen(2 entities) | 36 | $14,848 |
| Boehringer Ingelheim | 24 | $5,601 |
| Insulet Corporation | 3 | $263 |
| Medtronic(2 entities) | 3 | $209 |
| GRT US Holding, Inc. | 11 | $194 |
| Valeritas, Inc. | 9 | $172 |
| Averitas Pharma Inc. | 14 | $156 |
| Merck | 16 | $146 |
| Ascendis Pharma Endocrinology Inc | 4 | $140 |
| Bayer | 3 | $132 |
| Dexcom, Inc. | 6 | $124 |
| Cequr Corporation | 1 | $99 |
| IBSA Pharma Inc. | 6 | $87 |
| Tandem Diabetes Care, Inc. | 4 | $63 |
| Corcept Therapeutics | 4 | $61 |
| Abbott | 3 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $58 |
| Johnson & Johnson | 3 | $45 |
| Antares Pharma, Inc. | 3 | $41 |
| AbbVie | 3 | $35 |
| UCB, Inc. | 2 | $35 |
| Novartis | 1 | $30 |
| Shire North American Group Inc | 1 | $24 |
| Sequel Med Tech, LLC | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Pfizer | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| BD | 1 | $16 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Tolmar, Inc. | 1 | $13 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$178,205 in reported general payments places this provider in the 90th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Lansing
- Tobias ElseAnn Arbor$3.5M
- Elif OralAnn Arbor$2.9M
- Jamal HammoudFlint$2.6M
- Lowell SchmeltzFarmington Hills$2.3M
- George GrunbergerBloomfield Hills$1.9M
- Richard AuchusAnn Arbor$1.3M
- Ariel BarkanAnn Arbor$553K
- Gary EdelsonFarmington Hills$503K
- Michael BrennanSaint Clair Shores$433K
- Abdulsalam Al KassabRochester Hills$351K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.